Get the Stockscreener App
0.00
100.00%
-0.2012
After Hours:
.20
0.20
+
Essa Pharma Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.
See More
Previous Close:
$0.2012
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$9.52M
Revenue:
-
Net Income/Loss:
$-28.54M
P/E Ratio:
0.00
EPS:
-0.64
Net Cash Flow:
$-22.72M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$1.94
Essa Pharma Inc Stock (EPIX) Company Profile
Name
Essa Pharma Inc
Sector
Industry
Phone
(778) 331-0962
Address
SUITE 720, VANCOUVER, BC
Compare EPIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EPIX
Essa Pharma Inc
|
0.00 | 9.52M | 0 | -28.54M | -22.72M | -0.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Essa Pharma Inc Stock (EPIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-04-24 | Downgrade | Jefferies | Buy → Hold |
| Nov-04-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-04-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Mar-04-21 | Initiated | Piper Sandler | Overweight |
| Jan-11-21 | Reiterated | H.C. Wainwright | Buy |
| Nov-02-20 | Initiated | Jefferies | Buy |
| Oct-25-19 | Initiated | Oppenheimer | Outperform |
View All
Essa Pharma Inc Stock (EPIX) Latest News
Aug Macro: How rising interest rates impact ESSA Pharma Inc stockOptions Play & Real-Time Sentiment Analysis - moha.gov.vn
ESSA Pharma (EPIX) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Can ESSA Pharma Inc stock resist sector downturnsJuly 2025 Market Mood & Growth Focused Entry Reports - moha.gov.vn
Will ESSA Pharma Inc. stock pay special dividendsQuarterly Earnings Report & High Conviction Buy Zone Picks - DonanımHaber
Is ESSA Pharma Inc. stock resilient to inflationTrade Ideas & Expert Approved Momentum Ideas - Улправда
Is ESSA Pharma Inc. stock a top pick in earnings seasonMarket Performance Summary & Capital Efficient Trading Techniques - DonanımHaber
Is ESSA Pharma Inc. stock in correction or buying zonePortfolio Growth Summary & Free AI Powered Buy and Sell Recommendations - Улправда
Can ESSA Pharma Inc. stock resist sector downturns2025 Top Decliners & Low Risk High Win Rate Stock Picks - DonanımHaber
ESSA Pharma Amends Agreement with XenoTherapeutics, Adjusts Shareholder Terms - MSN
CanadaInvestors In Essa Pharma Inc. (NASDAQ: EPIX) Are Urged To Contact Siskinds LLP About Its Investigation Into A Potential Class Action - Mondaq
Support Test: Is ESSA Pharma Inc. stock in correction or buying zoneJuly 2025 Closing Moves & Weekly High Return Stock Opportunities - moha.gov.vn
Investors in Essa Pharma Inc. (NASDAQ: EPIX) are urged to contact Siskinds LLP about its investigation into a potential class action - The Globe and Mail
What analyst consensus says on ESSA Pharma Inc. stockWeekly Stock Summary & AI Powered Market Entry Ideas - Newser
Can ESSA Pharma Inc. stock deliver strong Q4 earningsTrade Volume Report & Real-Time Stock Price Movement Reports - newser.com
Is ESSA Pharma Inc. stock cheap compared to fundamentalsPortfolio Risk Report & Daily Chart Pattern Signal Reports - newser.com
Will ESSA Pharma Inc. stock split again soon2025 Macro Impact & Free Accurate Trade Setup Notifications - newser.com
Is ESSA Pharma Inc. stock a buy in volatile marketsInsider Buying & Weekly Market Pulse Alerts - newser.com
Is ESSA Pharma Inc. stock trading at a premium valuationJuly 2025 Trade Ideas & Safe Swing Trade Setup Alerts - newser.com
Using AI based signals to follow ESSA Pharma Inc.Gap Up & Free Fast Entry Momentum Trade Alerts - newser.com
Can ESSA Pharma Inc. stock resist market sell offs2025 Market Sentiment & Free High Accuracy Swing Entry Alerts - newser.com
What does recent volatility data suggest for ESSA Pharma Inc.Dip Buying & Low Drawdown Trading Techniques - newser.com
How moving averages guide ESSA Pharma Inc. tradingAnalyst Downgrade & Weekly High Momentum Picks - newser.com
How ESSA Pharma Inc. stock trades before earningsWatch List & Stepwise Trade Signal Guides - newser.com
Repare finds fix as biotech agrees to XenoTherapeutics buyout - Fierce Biotech
Will ESSA Pharma Inc. stock outperform value stocksMarket Activity Report & Free Technical Confirmation Trade Alerts - newser.com
What analysts say about ESSA Pharma Inc stockSector-Based Investing & What the Pros Are Saying About This Stock - earlytimes.in
Can ESSA Pharma Inc. stock attract ESG capital inflowsIPO Watch & AI Enhanced Market Trend Forecasts - Fundação Cultural do Pará
Does ESSA Pharma Inc. fit your quant trading modelJobs Report & Technical Pattern Based Buy Signals - newser.com
Tools to assess ESSA Pharma Inc.’s risk profileGap Down & Real-Time Stock Entry Alerts - newser.com
Essa Pharma Inc Stock (EPIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):